Other presentations
About half of patients are symptomatic at presentation, and those symptoms can be intermittent or constant. Symptoms include pruritus, upper abdominal pain, fatigue, fever, intermittent jaundice, anxiety, and depression.[3]Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 Feb 1;77(2):659-702.
https://www.doi.org/10.1002/hep.32771
http://www.ncbi.nlm.nih.gov/pubmed/36083140?tool=bestpractice.com
[4]Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004 Jun;126(7):1929-30.
http://www.ncbi.nlm.nih.gov/pubmed/15188211?tool=bestpractice.com
Symptoms will vary depending on the presence of biliary obstruction and/or acute cholangitis.
An increasing proportion of patients are identified through workup of asymptomatic elevated liver enzymes detected on routine laboratory testing.[5]Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007 May;102(5):1042-9.
http://www.ncbi.nlm.nih.gov/pubmed/17313496?tool=bestpractice.com
[6]Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003 Nov;125(5):1364-9.
http://www.ncbi.nlm.nih.gov/pubmed/14598252?tool=bestpractice.com
Patients with overlapping autoimmune hepatitis often have significantly higher serum levels of aminotransferases (alanine aminotransferase 357 IU/L vs. 83.7 IU/L) and IgG (25.6 g/L vs. 12.9 g/L).[7]Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005 Jul;100(7):1516-22.
http://www.ncbi.nlm.nih.gov/pubmed/15984974?tool=bestpractice.com
Patients who present with sudden and marked deterioration in clinical status and biochemical tests (e.g., worsening pruritus, fevers, and jaundice) may have a complication of PSC such as a dominant stricture (a stenosis with a diameter of ≤1.5 mm in the common bile duct or ≤1 mm in the hepatic duct identified by endoscopic retrograde cholangiopancreatography) or cholangiocarcinoma.[2]European Association for the Study of the Liver. EASL clinical practice guidelines on sclerosing cholangitis. J Hepatol. 2022 Sep;77(3):761-806.
https://www.doi.org/10.1016/j.jhep.2022.05.011
http://www.ncbi.nlm.nih.gov/pubmed/35738507?tool=bestpractice.com
[3]Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 Feb 1;77(2):659-702.
https://www.doi.org/10.1002/hep.32771
http://www.ncbi.nlm.nih.gov/pubmed/36083140?tool=bestpractice.com
At the time of diagnosis, a dominant bile duct stenosis may be present in up to 36% of patients.[8]Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007 Jan;102(1):107-14.
http://www.ncbi.nlm.nih.gov/pubmed/17037993?tool=bestpractice.com
A minority of patients present initially with complications of end-stage liver disease, such as ascites (2%), variceal bleeding (3%), or bacterial cholangitis (6%).[5]Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007 May;102(5):1042-9.
http://www.ncbi.nlm.nih.gov/pubmed/17313496?tool=bestpractice.com
[8]Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007 Jan;102(1):107-14.
http://www.ncbi.nlm.nih.gov/pubmed/17037993?tool=bestpractice.com